Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg).
Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks. Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh.
Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025).
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."